BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu P, Qian J, Xu Z, Meng C, Zhu W, Ran F, Zhang W, Zhang Y, Ling Y. Overview of piperlongumine analogues and their therapeutic potential. Eur J Med Chem 2021;220:113471. [PMID: 33930801 DOI: 10.1016/j.ejmech.2021.113471] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Goswami MJ, Dutta U, Seema T, Bharali SJ, Yanka H, Tag H, Bharali P, Kakati D. Antioxidant and Antidiabetic Properties of Extracts from Three Underutilized Food Plants of North East India. Chem Biodivers 2023;20:e202200718. [PMID: 36562215 DOI: 10.1002/cbdv.202200718] [Reference Citation Analysis]
2 Dong L, He J, Luo L, Wang K. Targeting the Interplay of Autophagy and ROS for Cancer Therapy: An Updated Overview on Phytochemicals. Pharmaceuticals (Basel) 2023;16. [PMID: 36678588 DOI: 10.3390/ph16010092] [Reference Citation Analysis]
3 Lan X, Hu M, Jiang L, Wang J, Meng Y, Chen X, Liu A, Ding W, Zhang H, Zhou H, Liu B, Peng G, Liao S, Chen X, Liu J, Shi X. Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells. Journal of Ethnopharmacology 2023;301:115815. [DOI: 10.1016/j.jep.2022.115815] [Reference Citation Analysis]
4 Li P, Guo X, Liu T, Liu Q, Yang J, Liu G. Evaluation of Hepatoprotective Effects of Piperlongumine Derivative PL 1-3-Loaded Albumin Nanoparticles on Lipopolysaccharide/d-Galactosamine-Induced Acute Liver Injury in Mice. Mol Pharm 2022;19:4576-87. [PMID: 35971845 DOI: 10.1021/acs.molpharmaceut.2c00215] [Reference Citation Analysis]
5 Alexa-Stratulat T, Pavel-Tanasa M, Cianga VA, Antoniu S. Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches. Expert Rev Anticancer Ther 2022;22:1197-210. [PMID: 36270650 DOI: 10.1080/14737140.2022.2139242] [Reference Citation Analysis]
6 Li J, Cai Z, Li XW, Zhuang C. Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives. J Med Chem 2022. [PMID: 36205223 DOI: 10.1021/acs.jmedchem.2c01223] [Reference Citation Analysis]
7 Qin J, Li H, Wang X, Zhang Y, Duan Y, Yao Y, Yang H, Sun M. Discovery of a novel piperlongumine analogue as a microtubule polymerization inhibitor with potent anti-angiogenic and anti-metastatic efficacy. Eur J Med Chem 2022;243:114738. [PMID: 36162214 DOI: 10.1016/j.ejmech.2022.114738] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bajalia EM, Azzouz FB, Chism DA, Giansiracusa DM, Wong CG, Plaskett KN, Bishayee A. Phytochemicals for the Prevention and Treatment of Renal Cell Carcinoma: Preclinical and Clinical Evidence and Molecular Mechanisms. Cancers 2022;14:3278. [DOI: 10.3390/cancers14133278] [Reference Citation Analysis]
9 Xu Z, Chu M. Advances in Immunosuppressive Agents Based on Signal Pathway. Front Pharmacol 2022;13:917162. [DOI: 10.3389/fphar.2022.917162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Ph K, Das S, G. D, Mahanta N. Therapeutic Implications of Piperlongumine. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022. [DOI: 10.1007/978-981-16-5422-0_190] [Reference Citation Analysis]
11 Qian J, Xu Z, Zhu P, Meng C, Liu Y, Shan W, He A, Gu Y, Ran F, Zhang Y, Ling Y. A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma. J Nat Prod 2021;84:3161-8. [PMID: 34806369 DOI: 10.1021/acs.jnatprod.1c00618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ph K, Das S, G D, Mahanta N. Therapeutic Implications of Piperlongumine. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2021. [DOI: 10.1007/978-981-16-1247-3_190-1] [Reference Citation Analysis]